Evidence map›Paper›PMID 32349579›Full record

ArticleImmunotherapy2020

COVID-19: the use of immunotherapy in metastatic lung cancer.

Alexander P Davis, Michael Boyer, Jenny H Lee, Steven C Kao

Open access · bronzeAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  9. Article
  10. Infections and Immunotherapy in Lung Cancer: A Bad Relationship?International journal of molecular sciences · 2020
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Alexander P DavisChris O'Brien Lifehouse, Department of Medical Oncology, 119-143 Missenden Road, Camperdown NSW 2050, Australia.
Michael BoyerChris O'Brien Lifehouse, Department of Medical Oncology, 119-143 Missenden Road, Camperdown NSW 2050, Australia.
Jenny H LeeChris O'Brien Lifehouse, Department of Medical Oncology, 119-143 Missenden Road, Camperdown NSW 2050, Australia.
Steven C KaoChris O'Brien Lifehouse, Department of Medical Oncology, 119-143 Missenden Road, Camperdown NSW 2050, Australia.
Chris O’Brien Lifehouse · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, Monoclonal, HumanizedCarcinoma, Non-Small-Cell LungCoronavirus InfectionsCOVID-19HumansImmunotherapyLung NeoplasmsPandemicsPneumonia, ViralProgrammed Cell Death 1 ReceptorRisk FactorsAntibodies, Monoclonal, HumanizedatezolizumabPDCD1 protein, humanProgrammed Cell Death 1 ReceptorCOVID-19duration of therapyimmune checkpoint inhibitorsimmunotherapylung cancer

Identifiers

PMID32349579
PMCPMC7202359
OpenAlexW3023620422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.